Effective implementation and adaptation of structured robotic colorectal programme in a busy tertiary unit.


Journal

Journal of robotic surgery
ISSN: 1863-2491
Titre abrégé: J Robot Surg
Pays: England
ID NLM: 101300401

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 24 07 2020
accepted: 24 10 2020
pubmed: 4 11 2020
medline: 29 10 2021
entrez: 3 11 2020
Statut: ppublish

Résumé

Safety and feasibility of robotic colorectal surgery has been reported as increasing over the last decade. However safe implementation and adaptation of such a programme with comparable morbidities and acceptable oncological outcomes remains a challenge in a busy tertiary unit. We present our experience of implementation and adaptation of a structured robotic colorectal programme in a high-volume center in the United Kingdom. Two colorectal surgeons underwent a structured robotic colorectal training programme consisting of time on simulation console, dry and wet laboratory courses, case observation, and initial mentoring. Data were collected on consecutive robotic colorectal cancer resections over a period of 12 months and compared with colorectal cancer resections data of the same surgeons' record prior to the adaptation of the new technique. Patient demographics including age, gender, American Society of Anesthesiologist score (ASA), Clavien-Dindo grading, previous abdominal surgeries, and BMI were included. Short-term outcomes including conversion to open, length of stay, return to theatre, 30- and 90-days mortality, blood loss, and post-operative analgesia were recorded. Tumour site, TNM staging, diverting stoma, neo-adjuvant therapy, total mesorectal excision (TME) grading and positive resection margins (R1) were compared. p values less than or equal to 0.05 were considered statistically significant. Ninety colorectal cancer resections were performed with curative intent from June 2018 to June 2020. Thirty robotic colorectal cancer resections (RCcR) were performed after adaption of programme and were compared with 60 non-robotic colorectal cancer resections (N-RCcR) prior to implementation of technique. There was no conversion in the RCcR group; however, in N-RCcR group, five had open resection from start and the rest had laparoscopic surgery. In laparoscopic group, there were six (10.9%) conversions to open (two adhesions, three multi-visceral involvements, one intra-operative bleed). Male-to-female ratio was 20:09 in RCcR group and 33:20 in N-RCcR groups. No significant differences in gender (p = 0.5), median age (p = 0.47), BMI (p = 0.64) and ASA scores (p = 0.72) were present in either groups. Patient characteristics between the two groups were comparable aside from an increased proportion of rectal and sigmoid cancers in RCcR group. Mean operating time, and returns to theaters were comparable in both groups. Complications were fewer in RCcR group as compared to N-RCcR (16.6% vs 25%). RCcR group patients have reduced length of stay (5 days vs 7 days) but this is not statistically significant. Estimated blood loss and conversion to open surgery was significantly lesser in the robotic group (p < 0.01). The oncological outcomes from surgery including TNM, resection margin status, lymph node yield and circumferential resection margin (for rectal cancers) were all comparable. There was no 30-day mortality in either group. Implementation and integration of robotic colorectal surgery is safe and effective in a busy tertiary center through a structured training programme with comparable short-term survival and oncological outcomes during learning curve.

Sections du résumé

BACKGROUND BACKGROUND
Safety and feasibility of robotic colorectal surgery has been reported as increasing over the last decade. However safe implementation and adaptation of such a programme with comparable morbidities and acceptable oncological outcomes remains a challenge in a busy tertiary unit. We present our experience of implementation and adaptation of a structured robotic colorectal programme in a high-volume center in the United Kingdom.
METHODS METHODS
Two colorectal surgeons underwent a structured robotic colorectal training programme consisting of time on simulation console, dry and wet laboratory courses, case observation, and initial mentoring. Data were collected on consecutive robotic colorectal cancer resections over a period of 12 months and compared with colorectal cancer resections data of the same surgeons' record prior to the adaptation of the new technique. Patient demographics including age, gender, American Society of Anesthesiologist score (ASA), Clavien-Dindo grading, previous abdominal surgeries, and BMI were included. Short-term outcomes including conversion to open, length of stay, return to theatre, 30- and 90-days mortality, blood loss, and post-operative analgesia were recorded. Tumour site, TNM staging, diverting stoma, neo-adjuvant therapy, total mesorectal excision (TME) grading and positive resection margins (R1) were compared. p values less than or equal to 0.05 were considered statistically significant.
RESULTS RESULTS
Ninety colorectal cancer resections were performed with curative intent from June 2018 to June 2020. Thirty robotic colorectal cancer resections (RCcR) were performed after adaption of programme and were compared with 60 non-robotic colorectal cancer resections (N-RCcR) prior to implementation of technique. There was no conversion in the RCcR group; however, in N-RCcR group, five had open resection from start and the rest had laparoscopic surgery. In laparoscopic group, there were six (10.9%) conversions to open (two adhesions, three multi-visceral involvements, one intra-operative bleed). Male-to-female ratio was 20:09 in RCcR group and 33:20 in N-RCcR groups. No significant differences in gender (p = 0.5), median age (p = 0.47), BMI (p = 0.64) and ASA scores (p = 0.72) were present in either groups. Patient characteristics between the two groups were comparable aside from an increased proportion of rectal and sigmoid cancers in RCcR group. Mean operating time, and returns to theaters were comparable in both groups. Complications were fewer in RCcR group as compared to N-RCcR (16.6% vs 25%). RCcR group patients have reduced length of stay (5 days vs 7 days) but this is not statistically significant. Estimated blood loss and conversion to open surgery was significantly lesser in the robotic group (p < 0.01). The oncological outcomes from surgery including TNM, resection margin status, lymph node yield and circumferential resection margin (for rectal cancers) were all comparable. There was no 30-day mortality in either group.
CONCLUSION CONCLUSIONS
Implementation and integration of robotic colorectal surgery is safe and effective in a busy tertiary center through a structured training programme with comparable short-term survival and oncological outcomes during learning curve.

Identifiants

pubmed: 33141410
doi: 10.1007/s11701-020-01169-1
pii: 10.1007/s11701-020-01169-1
pmc: PMC8423644
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

731-739

Informations de copyright

© 2020. The Author(s).

Références

Arthroscopy. 2015 Oct;31(10):1854-71
pubmed: 26341047
World J Surg Oncol. 2019 Jan 5;17(1):7
pubmed: 30611274
J Minim Access Surg. 2015 Jan-Mar;11(1):29-34
pubmed: 25598596
Lancet. 2002 Jun 29;359(9325):2224-9
pubmed: 12103285
Surg Endosc. 2013 Sep;27(9):3297-307
pubmed: 23508818
Surg Endosc. 2017 Oct;31(10):4067-4076
pubmed: 28271267
J Gastrointest Surg. 2014 Apr;18(4):816-30
pubmed: 24496745
Int J Med Robot. 2012 Mar;8(1):67-72
pubmed: 22556136
Int J Colorectal Dis. 2014 Jun;29(6):693-9
pubmed: 24770702
Surg Endosc. 2009 Feb;23(2):438-43
pubmed: 19037694
ISRN Surg. 2012;2012:293894
pubmed: 22655207
J Robot Surg. 2019 Oct;13(5):657-662
pubmed: 30536134
Ann Surg Oncol. 2014 Mar;21(3):829-40
pubmed: 24217787
Surg Endosc. 2015 Dec;29(12):3608-17
pubmed: 25743996
J Laparoendosc Adv Surg Tech A. 2018 Feb;28(2):117-126
pubmed: 28570140
BJU Int. 2016 Mar;117(3):515-30
pubmed: 26352342
Br J Surg. 2004 Sep;91(9):1111-24
pubmed: 15449261
Ann Surg. 2015 Jan;261(1):129-37
pubmed: 24662411
Ann Surg. 2012 Jun;255(6):1126-8
pubmed: 22498893
Asian J Surg. 2019 Jun;42(6):657-666
pubmed: 30609955
Surg Endosc. 2017 Jul;31(7):2820-2828
pubmed: 27815742
Can J Surg. 2008 Aug;51(4):296-9
pubmed: 18815654
BJU Int. 2014 Mar;113(3):504-8
pubmed: 23819461
Dis Colon Rectum. 2014 Sep;57(9):1066-74
pubmed: 25101602
Surg Endosc. 2012 Apr;26(4):956-63
pubmed: 22044968
World J Surg Oncol. 2014 Aug 28;12:274
pubmed: 25169141
Ann Surg Oncol. 2013 Aug;20(8):2625-32
pubmed: 23417433
World J Surg Oncol. 2016 Mar 01;14:61
pubmed: 26928124
Int J Colorectal Dis. 2016 Apr;31(4):869-76
pubmed: 26833474
Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4
pubmed: 17893502
Surg Endosc. 2015 Jun;29(6):1419-24
pubmed: 25159651
Surg Endosc. 2009 Apr;23(4):839-46
pubmed: 19116741
Lancet. 2005 May 14-20;365(9472):1718-26
pubmed: 15894098
Ann Surg. 2005 Jul;242(1):83-91
pubmed: 15973105
Surg Endosc. 2011 Jan;25(1):240-8
pubmed: 20552367
Langenbecks Arch Surg. 2018 Sep;403(6):749-760
pubmed: 29926187
Surg Endosc. 2017 Jun;31(6):2387-2396
pubmed: 27655383
Surg Endosc. 2015 Aug;29(8):2171-9
pubmed: 25361648
Surg Endosc. 2011 Feb;25(2):521-5
pubmed: 20607559

Auteurs

A Thomas (A)

Department of Surgery, Royal Liverpool and Broadgreen University Hospitals NHS Foundation Trust, Prescot Road, Liverpool, L7 8XP, UK.

K Altaf (K)

Department of Surgery, Royal Liverpool and Broadgreen University Hospitals NHS Foundation Trust, Prescot Road, Liverpool, L7 8XP, UK.

D Sochorova (D)

Department of Surgery, Royal Liverpool and Broadgreen University Hospitals NHS Foundation Trust, Prescot Road, Liverpool, L7 8XP, UK.

U Gur (U)

Department of Surgery, Royal Liverpool and Broadgreen University Hospitals NHS Foundation Trust, Prescot Road, Liverpool, L7 8XP, UK.

A Parvaiz (A)

Faculty of Health Science, University of Portsmouth, Portsmouth, UK.

Shakil Ahmed (S)

Department of Surgery, Royal Liverpool and Broadgreen University Hospitals NHS Foundation Trust, Prescot Road, Liverpool, L7 8XP, UK. Shakil.ahmed@liverpoolft.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH